Filing Details

Accession Number:
0001209191-21-006577
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-01 20:00:16
Reporting Period:
2021-01-29
Accepted Time:
2021-02-01 20:00:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1478320 Adaptive Biotechnologies Corp ADPT Biological Products, (No Disgnostic Substances) (2836) 270907024
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1780664 Julie Rubinstein C/O Adaptive Biotechnologies Corp.
Suite 200
Seattle WA 98102
President No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-01-29 15,000 $6.32 15,000 No 4 M Direct
Common Stock Disposition 2021-01-29 8,294 $55.77 6,706 No 4 S Direct
Common Stock Disposition 2021-01-29 4,910 $56.60 1,796 No 4 S Direct
Common Stock Disposition 2021-01-29 1,796 $57.74 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-01-29 15,000 $0.00 15,000 $6.32
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
95,000 2025-06-09 No 4 M Direct
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.
  2. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.20 to 56.07, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.26 to 57.14, inclusive.
  4. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.27 to 58.18, inclusive.
  5. The option is fully vested and exercisable.